Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Incyte (INCY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immatics (IMTX – Research Report) and Incyte (INCY – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immatics (IMTX)
Chardan Capital analyst Geulah Livshits maintained a Buy rating on Immatics today and set a price target of $25.00. The company’s shares closed last Thursday at $10.13.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of
Currently, the analyst consensus on Immatics is a Strong Buy with an average price target of $21.25, representing a 105.3% upside. In a report issued on February 19, Mizuho Securities also maintained a Buy rating on the stock with a $25.00 price target.
See the top stocks recommended by analysts >>
Incyte (INCY)
In a report released today, Matt Phipps from William Blair maintained a Hold rating on Incyte. The company’s shares closed last Thursday at $96.83.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $109.20.
